MEOX2 Serves as a Novel Biomarker Associated with Macrophage Infiltration in Esophageal Squamous Cell Carcinoma

zhen wang  
Sun Yat-sen University Cancer Center

han yang  
Sun Yat-sen University Cancer Center

rusi zhang  
Sun Yat-sen University Cancer Center

bin luo  
Sun Yat-sen University Cancer Center

bingchen xu  
Sun Yat-sen University Cancer Center

zihua zhu  
Sun Yat-sen University Cancer Center

peng lin (linpeng@sysucc.org.cn)  
Sun Yat-sen University Cancer Center

Research Article

Keywords: MEOX2, macrophage, esophageal squamous cell carcinoma, digestive system carcinomas, immune infiltration

DOI: https://doi.org/10.21203/rs.3.rs-139586/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

Esophageal squamous cell carcinoma (ESCC) is a kind of digestive system malignant tumor with high morbidity and mortality worldwide. With the rise of immunotherapy applied in cancer treatment, immune-related mechanisms in ESCC and other digestive system carcinomas are in urgent need of being detected.

Methods

In our study, single-sample gene set enrichment analysis (ssGSEA) was performed at first to analyze the expression profile downloaded from NCBI Gene Expression Omnibus (GEO) database. Then via a series of bioinformatic analyses, including Mann-Whitney test, weighted gene co-expression network analysis (WGCNA), functional enrichment analysis and differentially expressed genes (DEGs) analysis, we identified targeting immunocyte and related genes. Finally, we validated the results in TIMER database.

Results

Our analyses showed that macrophage infiltrating level is obviously higher in advanced stages in ESCC compared with other types of immunocytes. MEOX2 was detected as a biomarker correlated with macrophage infiltration in ESCC and other types of digestive system carcinomas. And MEOX2 expression was strongly associated with mRNA expression of colony-stimulating factor 1 (CSF-1) and CSF-1 receptor (CSF-1R) in these kinds of carcinomas.

Conclusion

We speculated that MEOX2 could facilitate macrophage infiltration via CSF-1/CSF-1R signaling in ESCC and other kinds of digestive system carcinomas, which might serve as a novel target in prospective tumor immunotherapy.

Background

As a common type of upper digestive tract malignant tumor, esophageal carcinoma (EC) is the sixth most common cause of cancer-related death around the world, and account for 509,000 cancer-related deaths each year.(1) Esophageal carcinoma is composed of two main histological types, esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESCC), of which squamous-cell carcinoma makes up about 90% of cases worldwide.(2) Although large amounts of breakthroughs have been achieved in diagnosis, screening, surgical resection and chemoradiotherapy of ESCC, the prognosis remain unsatisfactory.(3) Now the immunotherapy has gradually become a hot topic in oncology treatment, and its application in melanoma, pulmonary carcinoma and many other malignancies has been proven a great success.(4) However, immunotherapy in ESCC treatment still remain limited due to absence of reliable biomarkers related to immunocytes infiltrated in tumor microenvironment (TME) of
ESCC. Therefore, it is urgent to detect novel biomarkers of immune interaction with ESCC and identify new targets for immune-related therapy.

Previous studies have reported parts of immune microenvironment characteristics of ESCC. Esophageal carcinoma was considered to have an adequate mutational load for checkpoint inhibitor treatment, which opened up possibilities for immunotherapy in this disease. Schumacher et al. found that the CD8(+) T cell infiltration in esophageal carcinomas was a favorable prognostic factor and had potential therapeutic value. Nishimura et al. detected that mature LAMP-3 (lysosome-associated membrane glycoprotein 3) DCs (Dendritic cells) was correlated with increasing infiltrating CD8(+) T cells in ESCC, and that were identified to be associated with a better prognosis.

But in consideration of complicated factors implicated in the regulation of tumor immunity, more studies are required to complete the immune atlas in ESCC. Currently, with the development of bioinformatics, a great deal of public data containing gene expression and clinicopathologic information can be utilized to explore the tumor microenvironment of ESCC. Therefore, on the basis of public data and bioinformatic analysis, our study aimed to explore the association between infiltrating immunocytes and clinicopathologic characteristics, and to detect novel immune-relevant genes. In this study, via single-sample gene set enrichment analysis (ssGSEA), weighted gene co-expression network analysis (WGCNA), differentially expressed genes analysis (DEGs) and online database analysis, we identified a novel biomarker associated with immunocytes infiltrating in ESCC. The detailed workflow is shown in Fig. 1.

Materials And Methods

Data Collection and Preprocessing

The gene expression profile of GSE69925 was searched in NCBI Gene Expression Omnibus (GEO) with "esophageal squamous cell cancer" and "Homo sapiens" as keywords. GSE69925 consists of 274 biopsy specimens of ESCC, which were processed by Affymetrix Gene Chip HG-U133Plus2.0 to get comprehensive gene expression profiling. Of all 274 samples, 40 samples contain tumor staging information (3 samples of stage T2, 21 samples of stage T3 and 16 samples of stage T4).

Probes in this series were annotated by gene symbol information from soft formatted family files, the probe annotated by multiple genes was deleted, and the average value was recorded as the final expression value for the gene matched by multiple probes.

Implementation of Single-Sample Gene Set Enrichment Analysis (ssGSEA)

Immune-related gene sets were obtained from the cancer immunome database (TCIA). The literature from TCIA contains 28 immunocyte-related gene sets, including innate immunity and adaptive immunity. The innate immunity consists of activated dendritic cell, immature dendritic cell, plasmacytoid dendritic
cell, CD56dim natural killer cell, CD56bright natural killer cell, eosinophil, mast cell, macrophage, MDSC, monocyte, natural killer cell, natural killer T cell and neutrophil. While the adaptive immunity comprises of activated CD4 T cell, activated CD8 T cell, central memory CD4 T cell, central memory CD8 T cell, effector memory CD4 T cell, effector memory CD8 T cell, gamma delta T cell, activated B cell, immature B cell, memory B cell, T follicular helper cell, regulatory T cell, type 1 T helper cell, type 2 T helper cell and type 17 T helper cell.

Related infiltration levels for 28 immunocytes were quantified by the ssGSEA algorithm in R package GSVA, which could apply gene signatures expressed by immunocytes to every cancer samples.(10) Then the R package ESTIMATE was utilized to calculate the immune score, stromal score, tumor purity and estimate score of every tumor sample.(11)

Identification of Differentially Infiltrated Immunocytes between Different Stages

Based on T stages of samples containing tumor stage information, 40 samples were classified into two groups, T2+T3 and T4. Then we could identify immunocytes infiltrating differentially between two groups, which was analyzed by the Mann-Whitney test, and differences were considered statistically significant when P Value<0.05. The immunocyte with the greatest difference and clinical significance was selected as the target immunocyte for next analysis.

Identification of Infiltrating Immunocyte Related Gene List by Weighted Gene Co-expression Network Analysis (WGCNA)

The expressing profiling of all 274 samples was applied to this section. In this section, 5,000 genes with the highest average expression were selected, and the gene expression was calculated using the WGCNA algorithm.(12) First, the soft threshold for network construction was selected by calculating the scale-free topology fit index for several powers. Then, the scale-free network was constructed and the module eigengene (ME) was calculated. Each module contained a gene list with the most appropriate accounting of gene expression profile. And all 274 samples were divided into highly-infiltrating group and lowly-infiltrating group according to infiltrating scores of the targeting immunocyte, which was utilized as the clinicopathologic features for next step. Finally, the correlation between ME and clinicopathologic features in each module was calculated. According to module-trait relationships, the module displaying the most obvious correlation was considered a key module and selected for further calculation.(13)

Functional Enrichment Analysis
Metascape is a meta-analysis website integrating gene annotation and functional enrichment analysis. In this section, by using the “Express Analysis” module in Metascape, we explored the enriched biological processes and pathways of the gene list contained in the key module.(14)

**Differentially Expressed Genes (DEGs) and Correlation Analysis**

By DEGs analysis of gene list contained in the key module between highly-infiltrating and lowly-infiltrating group, we could further screen targeting genes associated with immunocyte infiltrating. DEGs were analyzed using package limma of R software with adjusted P Value<0.05 and |logFC| >1.(15)

Spearman’s correlation test was performed to evaluate potential correlations between mRNA expression of target genes and immunocyte infiltration levels.(16)

**TIMER Database Analysis**

TIMER is a comprehensive website for systematic analysis of infiltrating immunocytes across diverse carcinomas.(17) We analyzed expressions of target genes in different types of carcinoma and their correlations with 6 types of infiltrating immunocytes (B cells, CD4+ T cells, CD8+ T cells, neutrophils, macrophages, and dendritic cells) in esophageal carcinoma and other digestive system carcinomas. Gene expression levels against tumor purity is a critical factor that have an effect on the analysis of immunocyte infiltrating level and is shown in the left-most panel.(11) The correlations between mRNA expressions of target genes and that of related colony-stimulating factors (CSFs) were also analyzed in TIMER.

**Results**

**Data Information**

GSE69925 was submitted by Japan National Cancer Center Research Institute, and was constitutive of 274 pretreatment biopsy specimens of esophageal squamous cell carcinoma, which were performed by comprehensive gene expression profiling. After preprocessing, 21,654 genes were annotated and retained for following analysis.

**Infiltrated Immunocytes Relevant to Different Stages in ESCC**

The immune infiltration levels of 40 samples with stage information is visualized as a heat map (Figure 2A). Between two groups (T2+T3 and T4), our analysis showed that 7 types of immunocytes had
significantly different infiltrating levels, including central memory CD8 T cell, gamma delta T cell, immature B cell, macrophage, monocyte, natural killer T cell and type 2 T helper cell. Among these types of immunocytes, macrophage had a greater statistic difference (P<0.001, Figure 2B) and had been reported to participate in the tumor promoting activities in esophageal carcinoma. Thus, macrophage was selected as a targeting immunocyte in our study.

**Identification of Macrophage Infiltration Related Gene List**

The immune infiltration levels of all 274 samples are shown in figure 3A. As depicted in the figure, all samples are divided into high macrophage infiltration group (Macro-H) and low macrophage infiltration group (Macro-L) according to the median value of macrophage infiltrating levels (median value, 0.418).

Based on 5,000 genes with the highest average expression in 274 samples, gene co-expression modules were analyzed by WGCNA algorithm. In our analysis, when power value is 3, the scale-free co-expression network can be achieved (Figure 3B). Then 6 modules containing the 5,000 genes above-mentioned were constructed. All the modules are marked with different colors and shown in figure 3C. Using macrophage infiltrating levels as clinicopathologic features, we could plot module-feature relationships (Figure 3D). From the figure, we could detect that high macrophage infiltrating group (Macro-H) was strongly associated with the yellow module (r = 0.43, P = 1E-13). Gene significance of 125 genes contained in the yellow module versus module membership is depicted in a scatter plot (Figure 3E). Therefore, the gene list contained in the yellow module was considered to be significant for macrophage infiltration in ESCC and selected as the hub gene list.

**Functional Enrichment Analysis of Hub Gene List**

Biological processes of the gene list were explored utilizing GO and KEGG analysis in Metascape (Figure 4). As shown in this figure, the top 5 enrichment items are: GO:0046649: lymphocyte activation; GO:0050900: leukocyte migration; ko04640: Hematopoietic cell lineage; GO:0009617: response to bacterium; and GO:0070661: leukocyte proliferation. Results of enrichment analysis indicated that the hub gene list was highly connected with immune system functions.

**Identification of Macrophage Infiltration Related Genes**

The hub gene list was further screened by differentially expressed genes (DEGs) analysis between high macrophage infiltration group and low macrophage infiltration group. In this step, 29 genes expressing differentially were extracted via limma package in R (Table 1, Figure 5A). Considering that the selected gene list was strongly correlated with high level of macrophage infiltration, every DEGs was upregulated gene (adj.P.Val<0.05, logFC>1).
The DEGs contained some genes that were members of TCIA immune gene sets used for ssGSEA, which were excluded firstly. Then, the genes that expressed specifically in immune cells were eliminated. Finally, we focused on MEOX2, which was also known as GAX and MOX2 according to genebank in NCBI.(19)

Expression level of MEOX2 in two groups was visualized as a violin plot in figure 5B. The correlation between MEOX2 expression and macrophage infiltrating level was calculated by Spearman's correlation test, which is shown in figure 5C (r=0.31, P=1.16e-7).
## Table 1
All 29 differentially expressed genes (DEGs).

| Gene names | logFC   | adj.P.Val     | Threshold  |
|------------|---------|---------------|------------|
| FGL2       | 1.3582  | 8.50E-14      | Up-regulated |
| SELL       | 1.34365 | 8.50E-14      | Up-regulated |
| LYZ        | 1.259134| 1.68E-12      | Up-regulated |
| HLA-DRA    | 1.361538| 4.97E-12      | Up-regulated |
| HLA-DPB1   | 1.071925| 3.51E-11      | Up-regulated |
| AMICA1     | 1.34624 | 5.53E-11      | Up-regulated |
| P2RY13     | 1.317397| 1.57E-10      | Up-regulated |
| CXCL13     | 1.556873| 3.94E-10      | Up-regulated |
| RGS1       | 1.155115| 4.42E-10      | Up-regulated |
| NKG7       | 1.220654| 4.12E-09      | Up-regulated |
| VNN2       | 1.250275| 4.12E-09      | Up-regulated |
| HLA-DPA1   | 1.141101| 4.30E-09      | Up-regulated |
| C16orf54   | 1.124131| 9.54E-09      | Up-regulated |
| SIRPG      | 1.053681| 1.56E-08      | Up-regulated |
| mir-223    | 1.007042| 1.01E-07      | Up-regulated |
| FAM46C     | 1.005428| 1.01E-07      | Up-regulated |
| DPEP2      | 1.048941| 1.46E-07      | Up-regulated |
| SELE       | 1.152871| 1.70E-07      | Up-regulated |
| GZMK       | 1.171047| 4.26E-07      | Up-regulated |
| S100B      | 1.144958| 8.14E-07      | Up-regulated |
| IKZF3      | 1.148145| 8.14E-07      | Up-regulated |
| CRTAM      | 1.058799| 1.24E-06      | Up-regulated |
| MEOX2      | 1.156775| 1.40E-06      | Up-regulated |
| TNFRSF17   | 1.329981| 5.90E-06      | Up-regulated |
| ANKRD36BP2 | 1.164973| 6.27E-06      | Up-regulated |
| IGJ        | 1.346993| 9.74E-06      | Up-regulated |
| IGHM       | 1.062385| 1.71E-05      | Up-regulated |
Confirmation of Correlation between MEOX2 Expression and Macrophage Infiltrating Level in TIMER Database

TIMER database was utilized to verify the correlation between MEOX2 expression level and degree of immunocytes infiltration in esophageal carcinoma (Figure 6A). As shown in figure, MEOX2 expression levels have a highly positive correlation with infiltrating levels of macrophage (r = 0.449, P = 2.52e-10). Then we further assessed the correlations between MEOX2 expression level and degree of immunocytes infiltration in other digestive system carcinomas, including stomach adenocarcinoma (STAD), pancreatic adenocarcinoma (PAAD), colon adenocarcinoma (COAD) and rectum adenocarcinoma (READ) (Figure 6B-6E). The results indicated that MEOX2 expression levels had a significantly positive correlation with infiltrating levels of macrophages in all kinds of carcinomas mentioned above, including STAD (r = 0.634, P = 4.53e-43), PAAD (r = 0.629, P = 3.24e-20), COAD (r = 0.646, P = 5.40e-49) and READ (r = 0.495, P = 6.07e-10).

Colony-stimulating factor 1 (CSF-1) is known as essential for proliferation and differentiation of macrophages. Then we explored correlations between mRNA expressions of MEOX2 and mRNA expressions of colony-stimulating factor 1 (CSF-1) and colony-stimulating factor 1 receptor (CSF-1R) in TIMER database. The results showed that MEOX2 expression had positive correlations with mRNA expressions of CSF-1 (r = 0.336, P = 2.84e-6) and CSF-1R (r = 0.475, P = 8.07e-12) in esophageal carcinoma (Figure 7). Further analysis indicated that in all the other digestive system carcinomas MEOX2 expression had positive correlations with mRNA expressions of CSF-1 and CSF-1R as well, correlations in these kinds of carcinomas were even more obvious than that in esophageal carcinoma (Figure 7).

Discussion

In this study, we found that macrophage infiltrating level is obviously higher in advanced stages in ESCC. Then by a series of bioinformatic analysis, MEOX2 was detected as a biomarker with a positive correlation with macrophage infiltration in ESCC and other types of digestive system carcinomas. As far as we know, in our study MEOX2 is first reported as a biomarker associating with immunocytes infiltration in carcinoma.

Tumor associated macrophages (TAMs) are defined as macrophages settled in the tumor tissues, which are essential members of immunocytes that constitute tumor microenvironment (TME) and play complicated roles in tumorigenesis, tumor development and metastasis. (20) In initial stage of tumor, attracted by tumor cell derived colony-stimulating factors (CSFs), macrophages from surrounding tissues...
would infiltrate in the tumor tissue and construct supporting microenvironment for tumor cells. (21) Then macrophages secreted various kinds of pro-tumorigenic cytokines, which could promote tumor cell proliferation, inhibit anti-tumor immunity, and upregulate angiogenesis in tumor tissues. (22–25) With the progress of tumor, some collagenases like MMP2 and MMP9 derived from macrophages could degrade basement membrane and promote angiogenesis, which played indispensable roles in tumor invasion and metastasis. (26)

As an indispensable factor for macrophage differentiation and survival, colony-stimulating factor 1 (CSF-1) has been detected to be largely expressed in several kinds of carcinoma cells. (22, 27, 28) The CSF-1 receptor (CSF-1R) belongs to transmembrane tyrosine kinase receptor and is specially expressed in monocytic lineage. (27) And CSF-1/ CSF-1R mediated signaling was reported to be associated with worse prognosis in a variety of carcinomas, including breast and hepatic cancer. (29, 30) Therefore, blockades targeting CSF-1/ CSF-1R has drawn more and more attention recently, such as humanized monoclonal antibody RG7155 and small molecular compound PLX3397, which has displayed efficacy in several preclinical models. (31, 32)

Role of TAMs in esophageal carcinoma has also been reported in many literatures. Manabu Shigeoka et al. found that high TAM density was correlated with poor prognosis in ESCC. (33) In our study, macrophage infiltrating level in stage T4 is apparently higher than that in stage T2-3, which is consistent with the previous study. Taisuke Yagi et al. detected that TAMs could upregulate programmed death ligand 1 (PD-L1) expression in esophageal carcinoma cells, which would be likely to have clinical implications on immune checkpoint therapy. (34) In addition, TAMs were identified as a biomarker for predicting chemotherapy response in esophageal carcinoma as well. (35)

Mesenchyme Homeobox 2 (MEOX2) is a protein coding gene, which is also known as GAX (growth arrest homeobox) or MOX2. (36) Encoding production of MEOX2 is a homeodomain transcription factor, which has traditionally been regarded as essential for bone and muscle growth in embryos. (37) In recent years, MEOX2 has been detected that it could suppress cell proliferation and EMT (epithelial-to-mesenchymal transition) in cell models. (38, 39) In addition, MEOX2 has also been reported to play vital roles in platinum-based drug resistance and EGFR-TKI-based (epidermal growth factor receptor- tyrosine kinase inhibitor) treatment response in non-small cell lung cancer (NSCLC) patients, which means poor prognoses in these patients. (40) Whereas the role of MEOX2 in immune infiltration of TME has never been described.

In our study, mRNA expression of MEOX2 was positively correlated with macrophage infiltrating level in esophageal squamous cell carcinoma, which was confirmed by the following analysis in TIMER database. Such correlations could be detected in other kinds of digestive system carcinomas as well, which were even more obvious. Further analysis told us that MEOX2 expression was strongly associated with mRNA expression of CSF-1 and CSF-1R in esophageal carcinoma and all the other digestive system carcinomas. Collectively, we speculated that MEOX2 could promote macrophage infiltrating into tumor
microenvironment via CSF-1/CSF-1R signaling in esophageal carcinoma and other digestive system carcinomas.

We acknowledge that there are several limitations in this study. Histological type of samples contained in GSE69925 is squamous cell carcinoma, whereas the majority of esophageal samples utilized in TIMER database are adenocarcinoma. In addition, our study was based on bioinformatic analysis of expression profile from public databases, further biological experiments were required to confirm the results.

Conclusions

In summary, our study provides a novel perspective into the function of MEOX2 in macrophage infiltration in ESCC and other kinds of digestive system carcinomas. In carcinomas mentioned above, MEOX2 expression was not only associated with macrophage infiltrating level but also positively correlated with mRNA expression of CSF-1 and CSF-1R. Therefore, we supposed that MEOX2 could facilitate macrophage infiltration via CSF-1/CSF-1R signaling in these kinds of carcinomas.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and materials

The datasets analyzed during the current study are available in the NCBI Gene Expression Omnibus (GEO) repository (https://www.ncbi.nlm.nih.gov/geo/).

Competing interests

The authors declare that they have no competing interests.

Funding

Not applicable.
Authors' contributions

Peng Lin and Zhihua Zhu conceived this study; Rusi Zhang, Bin Luo and Bingchen Xu retrieved and disposed data from GEO database; Zhen Wang and Han Yang performed data analysis prepared the manuscript; Peng Lin and Zhihua Zhu revised the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We thank the contributors to the profile of GSE69925 in the GEO datasets (https://www.ncbi.nlm.nih.gov/geoprofiles).

Authors' information (optional)

Not applicable.

References

1. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pineros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941-53.

2. Rustgi AK, El-Serag HB. Esophageal carcinoma. N Engl J Med. 2014;371(26):2499-509.

3. Watanabe M, Otake R, Kozuki R, Toihata T, Takahashi K, Okamura A, et al. Recent progress in multidisciplinary treatment for patients with esophageal cancer. Surg Today. 2020;50(1):12-20.

4. Ammannagari N, Atasoy A. Current status of immunotherapy and immune biomarkers in gastro-esophageal cancers. J Gastrointest Oncol. 2018;9(1):196-207.

5. Dhupar R, Van Der Kraak L, Pennathur A, Schuchert MJ, Nason KS, Luketich JD, et al. Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor. Ann Thorac Surg. 2017;103(4):1340-9.

6. Schumacher K, Haensch W, Roefzaad C, Schlag PM. Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res. 2001;61(10):3932-6.

7. Nishimura J, Tanaka H, Yamakoshi Y, Hiramatsu S, Tamura T, Toyokawa T, et al. Impact of tumor-infiltrating LAMP-3 dendritic cells on the prognosis of esophageal squamous cell carcinoma. Esophagus. 2019;16(4):333-44.

8. Tanaka Y, Aoyagi K, Minashi K, Komatsuzaki R, Komatsu M, Chiwaki F, et al. Discovery of a Good Responder Subtype of Esophageal Squamous Cell Carcinoma with Cytotoxic T-Lymphocyte Signatures Activated by Chemoradiotherapy. PLoS One. 2015;10(12):e0143804.
9. Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, et al. Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade. Cell Rep. 2017;18(1):248-62.

10. Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.

11. Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.

12. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559.

13. Li J, Liu C, Chen Y, Gao C, Wang M, Ma X, et al. Tumor Characterization in Breast Cancer Identifies Immune-Relevant Gene Signatures Associated With Prognosis. Front Genet. 2019;10:1119.

14. Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1523.

15. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.

16. Holderried TAW, de Vos L, Bawden EG, Vogt TJ, Dietrich J, Zarbl R, et al. Molecular and immune correlates of TIM-3 (HAVCR2) and galectin 9 (LGALS9) mRNA expression and DNA methylation in melanoma. Clin Epigenetics. 2019;11(1):161.

17. Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509-W14.

18. Huang TX, Fu L. The immune landscape of esophageal cancer. Cancer Commun (Lond). 2019;39(1):79.

19. Mascher M, Schreiber M, Scholz U, Graner A, Reif JC, Stein N. Genebank genomics bridges the gap between the conservation of crop diversity and plant breeding. Nat Genet. 2019;51(7):1076-81.

20. Ostuni R, Kratochvill F, Murray PJ, Natoli G. Macrophages and cancer: from mechanisms to therapeutic implications. Trends Immunol. 2015;36(4):229-39.

21. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004;4(1):71-8.

22. Komohara Y, Fujiwara Y, Ohnishi K, Takeya M. Tumor-associated macrophages: Potential therapeutic targets for anti-cancer therapy. Adv Drug Deliv Rev. 2016;99(Pt B):180-5.

23. Wu A, Wei J, Kong LY, Wang Y, Pribe W, Qiao W, et al. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol. 2010;12(11):1113-25.

24. Vlaicu P, Mertins P, Mayr T, Widschwendter P, Ataseven B, Hogel B, et al. Monocytes/macrophages support mammary tumor invasivity by co-secreting lineage-specific EGFR ligands and a STAT3 activator. BMC Cancer. 2013;13:197.
25. Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res. 2006;66(23):11238-46.

26. Wyckoff JB, Wang Y, Lin EY, Li JF, Goswami S, Stanley ER, et al. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res. 2007;67(6):2649-56.

27. Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14(7):399-416.

28. Cannarile MA, Weisser M, Jacob W, Jegg AM, Ries CH, Ruttinger D. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J Immunother Cancer. 2017;5(1):53.

29. Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ, et al. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol. 2008;26(16):2707-16.

30. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med. 2001;193(6):727-40.

31. Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014;25(6):846-59.

32. Tap WD, Wainberg ZA, Anthony SP, Ibrahim PN, Zhang C, Healey JH, et al. Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. N Engl J Med. 2015;373(5):428-37.

33. Shigeoka M, Urakawa N, Nakamura T, Nishio M, Watajima T, Kuroda D, et al. Tumor associated macrophage expressing CD204 is associated with tumor aggressiveness of esophageal squamous cell carcinoma. Cancer Sci. 2013;104(8):1112-9.

34. Yagi T, Baba Y, Okadome K, Kiyozumi Y, Hiyoshi Y, Ishimoto T, et al. Tumour-associated macrophages are associated with poor prognosis and programmed death ligand 1 expression in oesophageal cancer. Eur J Cancer. 2019;111:38-49.

35. Yamamoto K, Makino T, Sato E, Noma T, Urakawa S, Takeoka T, et al. Tumor-infiltrating M2 macrophage in pretreatment biopsy sample predicts response to chemotherapy and survival in esophageal cancer. Cancer Sci. 2020;111(4):1103-12.

36. Brown GR, Hem V, Katz KS, Ovetsky M, Wallin C, Ermolaeva O, et al. Gene: a gene-centered information resource at NCBI. Nucleic Acids Res. 2015;43(Database issue):D36-42.

37. Mankoo BS, Collins NS, Ashby P, Grigorieva E, Pevny LH, Candia A, et al. Mox2 is a component of the genetic hierarchy controlling limb muscle development. Nature. 1999;400(6739):69-73.

38. Valcourt U, Thuault S, Pardali K, Heldin CH, Moustakas A. Functional role of Meox2 during the epithelial cytostatic response to TGF-beta. Mol Oncol. 2007;1(1):55-71.

39. Patel S, Leal AD, Gorski DH. The homeobox gene Gax inhibits angiogenesis through inhibition of nuclear factor-kappaB-dependent endothelial cell gene expression. Cancer Res. 2005;65(4):1414-24.

40. Armas-Lopez L, Pina-Sanchez P, Arrieta O, de Alba EG, Ortiz-Quintero B, Santillan-Doherty P, et al. Epigenomic study identifies a novel mesenchyme homeobox homeobox2-GLI1 transcription axis involved in
cancer drug resistance, overall survival and therapy prognosis in lung cancer patients. Oncotarget. 2017;8(40):67056-81.

Figures

Figure 2

(A) Immune infiltration levels of 40 samples with stage information. (B) Macrophage infiltrating level was obviously higher in advanced stages in esophageal squamous cell carcinoma (ESCC) (***, P<0.001).
Figure 4

Functional enrichment analysis of gene list contained in the yellow module. (A) Network of functional enrichment terms colored by clusters. (B) Heatmap of functional enrichment terms colored by P-values.
Figure 5

Identification of macrophage infiltration related genes. (A) Volcano plot of differentially expressed genes (DEGs) between high macrophage infiltration group and low macrophage infiltration group. (B) Violin plot of MEOX2 expression level in two groups (***, P<0.001). (C) Correlation between MEOX2 expression and macrophage infiltrating level.